Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran autogene vaccine with Merck's KEYTRUDA, fueling investor optimism despite no new announcements. Moderna expects an interim analysis from its Phase 3 melanoma trial later in 2026, which could further impact the stock. Peer BioNTech showed minimal movement, indicating the market is focused on Moderna's specific vaccine program rather than the broader mRNA cancer vaccine sector.
Moderna trades at USD 159.22 on Pluang, up 9.34% as of Sep 17, 2026 21:02 WIB, showing strong investor interest. BioNTech and Novavax also rise, with BioNTech up 3.70% at USD 99.38 and Novavax up 5.88% at USD 9.90. Pluang order activity favors buying Novavax at 100% and Moderna at 67%, reflecting confidence in these health sector stocks.
